Sonomind will showcase its non-invasive low-intensity focused ultrasound neuromodulation platform designed for treatment-resistant depression (as a first indication). The demonstration will present the treatment workflow, from brain imaging to patient-specific acoustic lens design and ultrasound therapy delivery. Visitors will discover how Sonomind combines precision targeting, ease of use, and patient comfort through an innovative medical device developed to open new possibilities in psychiatric and neurology care.
